SYSTEMATIC REVIEW/META-ANALYSIS
Development of erectile dysfunction in men treated for major depressive disorder with selective serotonin reuptake inhibitors: a systematic review
 
More details
Hide details
1
Department of Internal Medicine, College of Medicine, Jouf University, Sakaka, Saudi Arabia
Submission date: 2020-01-31
Final revision date: 2020-07-01
Acceptance date: 2020-08-02
Online publication date: 2020-08-25
 
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
: Sexual dysfunction (SD) is known to be associated with selective serotonin reuptake inhibitors (SSRIs). To determine the effect of different SSRIs on SD development in males, particularly erectile dysfunction (ED), a systematic review was conducted according to PRISMA guidelines.

Material and methods:
Literature, in English language, published between January 2009 and September 2019 was searched using two electronic databases, PubMed and EMBASE. Studies were screened according to the predefined inclusion-exclusion criteria. The bibliographies of the included articles were screened to identify any relevant articles.

Results:
A total of ten articles were included (8/811 articles searched; two from bibliographies of eight included articles). Treatment-emergent SD, particularly ED was observed in male participants, although the ED incidence was low, less than 2%. SSRIs – fluoxetine, escitalopram, and citalopram – showed a higher risk of ED than other SSRIs.

Conclusions:
The findings indicated a positive association between SSRIs and SD. However, evidence supporting a strong link between SSRIs and ED was insufficient.

eISSN:1896-9151
ISSN:1734-1922